

# Fc $\gamma$ RIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell Fc $\gamma$ RIIIa, Independently of the Fc $\gamma$ RIIIa-48L/R/H Phenotype

By Harry R. Koene, Marion Kleijer, Johan Algra, Dirk Roos, Albert E.G.Kr. von dem Borne, and Masja de Haas

We analyzed a genetic polymorphism of Fc $\gamma$  receptor IIIa (CD16) that is present on position 158 (Phe or Val) in the membrane-proximal, IgG-binding domain. With a polymerase chain reaction–based allele-specific restriction analysis assay we genotyped 87 donors and found gene frequencies of 0.57 and 0.43 for Fc $\gamma$ RIIIA-158F and –158V, respectively. A clear linkage was observed between the Fc $\gamma$ RIIIA-158F and –48L genotypes on the one hand and the Fc $\gamma$ RIIIA-158V and –48H or –48R genotypes on the other hand ( $\chi^2$  test;  $P < .001$ ). To determine the functional consequences of this Fc $\gamma$ RIIIa-158V/F polymorphism, we performed IgG binding experiments with natural killer (NK) cells from genotyped donors. All donors were also typed for the recently described triallelic Fc $\gamma$ RIIIa-48L/R/H polymorphism. NK cells were treated with lactic acid to remove cell-associated IgG. Fc $\gamma$ RIIIa<sup>NK</sup>.

SEVERAL IgG Fc receptor (Fc $\gamma$ R) polymorphisms that influence the binding of IgG have been described.<sup>1</sup> On neutrophils, the Fc $\gamma$ RIIIb-NA1 and -NA2 isoforms, which differ by four amino acids in the membrane-distal Ig-like loop of the receptor, interact differently with IgG-opsonized particles,<sup>2-4</sup> and influence the interaction of the receptor with Fc $\gamma$ RIIa.<sup>5</sup> On Fc $\gamma$ RIIa, the extensively investigated high responder/low responder polymorphism on amino-acid position 131 in the membrane-proximal, IgG-binding domain is critical for the interaction with human IgG2.<sup>6</sup> Moreover, the Fc $\gamma$ RIIIa-131R/H polymorphism was found to be associated with several diseases, such as bacterial infections in children, heparin-induced thrombocytopenia, juvenile periodontitis, and systemic lupus erythematosus.<sup>7-12</sup>

Previously, Ravetch and Perussia described a polymorphism in the membrane-proximal domain of Fc $\gamma$ RIIIa.<sup>13</sup> A nucleotide substitution at position 559 of Fc $\gamma$ RIIIA predicts either a valine or a phenylalanine at amino-acid position 158 of Fc $\gamma$ RIIIa. Because the IgG binding site is most probably located in this part of Fc $\gamma$ RIIIa,<sup>14,15</sup> we determined the gene frequency and functional consequences of this polymorphism in the context of the recently described Fc $\gamma$ RIIIa-48L/R/H polymorphism. As expected, a clear although incomplete linkage was observed between the two polymorphisms. Moreover, we found that the previously described differences in binding between the Fc $\gamma$ RIIIa-48 isoforms of IgG and of some of the CD16 monoclonal antibodies (MoAbs) are attributable to the Fc $\gamma$ RIIIa-158 phenotype.

## MATERIALS AND METHODS

**MoAbs.** Anti-pan Fc $\gamma$ RIII (CD16) MoAbs used were CLBFCrgran1 (mIgG2a) and MEM154 (mIgG1). B73.1 (mIgG1) reacts with NA1-Fc $\gamma$ RIIIb and with Fc $\gamma$ RIIIa,<sup>16</sup> and was kindly provided by Dr B. Perussia (Thomas Jefferson University, Philadelphia, PA). MEM154 was obtained through the 5th Leukocyte Typing Workshop. Phycoerythrin (PE)-labeled Leu19 (CD56; mIgG1) was purchased from Becton Dickinson (San Jose, CA). Fluorescein isothiocyanate (FITC)-conjugated goat–antimouse Ig and irrelevant control MoAbs of the IgG1 and IgG2a subclasses were from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam, The Netherlands.

**Isolation of cells.** Fresh, EDTA-anticoagulated blood from

158F bound significantly less IgG1, IgG3, and IgG4 than did Fc $\gamma$ RIIIa<sup>NK</sup>-158V, irrespective of the Fc $\gamma$ RIIIa-48 phenotype. Moreover, freshly isolated NK cells from Fc $\gamma$ RIIIa-158VV individuals carried significantly more cytophilic IgG than did NK cells from Fc $\gamma$ RIIIa-158FF individuals. In addition, CD16 monoclonal antibody (MoAb) MEM154 bound more strongly to Fc $\gamma$ RIIIa-158V, compared with -158F, again independently of the Fc $\gamma$ RIIIa-48 phenotype. The binding of MoAb B73.1 was not influenced by the Fc $\gamma$ RIIIa-158V/F polymorphism, but proved to depend solely on the amino acid present at position 48 of Fc $\gamma$ RIIIa. In conclusion, the previously reported differences in IgG binding among the three Fc $\gamma$ RIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc $\gamma$ RIIIa-158V/F polymorphism at amino-acid position 158.

© 1997 by The American Society of Hematology.

healthy volunteers was diluted with two volumes of phosphate-buffered saline (PBS) and was centrifuged over a Ficoll gradient (Pharmacia Fine Chemicals AB, Uppsala, Sweden) with a specific gravity of 1.076 g/mL. Peripheral blood mononuclear cells (PBMC) were obtained from the interphase and were washed twice with PBS, containing 0.2% (wt/vol) bovine serum albumin (BSA).

**Flow cytometry.** PBMC were incubated with CD16 MoAbs for 25 minutes at room temperature. The cells were washed with PBS/BSA, and were incubated with FITC-labeled goat–antimouse-Ig for 25 minutes at room temperature. Free F(ab')<sub>2</sub> regions of the conjugate were blocked with a mixture of irrelevant mIgG1 and mIgG2a. Thereafter, the cells were incubated with PE-labeled CD56. Only CD56<sup>+</sup> lymphocytes were analyzed in a FACScan flowcytometer (Becton Dickinson).

**Fc $\gamma$ RIIIA-48L/R/H genotyping.** Genotyping for the Fc $\gamma$ RIIIA-48L/R/H polymorphism was performed as previously described,<sup>17</sup> with a polymerase chain reaction (PCR)-based allele-specific restriction analysis assay. Briefly, a 91-bp Fc $\gamma$ RIIIA-specific fragment containing the polymorphic site was amplified from genomic DNA and digested with *Mnl* I. Digested fragments were electrophoresed in 10% acryl amide gels, stained with ethidium bromide, and visualized with UV light. Homozygous Fc $\gamma$ RIIIA-48LL individuals showed 40-bp, 34-bp, and 17-bp bands, whereas PCR fragments of individuals carrying no or only one Fc $\gamma$ RIIIA-48L allele showed a 51-bp band. The genotype of these latter individuals was determined by direct sequencing of the amplified fragments, using one of the PCR primers, end-labeled with <sup>32</sup>P (Amersham International, Buckinghamshire, UK), with the Life Technologies cycle sequencing kit, follow-

From the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam; and Academic Medical Centre, Amsterdam, The Netherlands.

Submitted January 29, 1997; accepted March 19, 1997.

Supported by Grant No. 900-512-092 from the Netherlands Organization for Scientific Research (NWO).

Address reprint requests to Masja de Haas, PhD, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.

0006-4971/97/9003-0024\$3.00/0

ing the instructions of the manufacturer (Life Technologies, Gaithersburg, MD).

***FcγRIIIA-158V/F genotyping.*** Genotyping of the *FcγRIIIA-158V/F* polymorphism was performed by means of a (nested) PCR-based allele-specific restriction analysis assay. Two *FcγRIIIA* gene-specific primers (sense A013: 5'-ATA TTT ACA GAA TGG CAC AGG-3'; antisense A012: 5'-GAC TTG GTA CCC AGG TTG AA-3'; italic characters denote mismatches that were introduced to increase specificity) were used to amplify a 1.2-kb fragment containing the polymorphic site. This PCR assay was performed with 5 ng of genomic DNA, 150 ng of each primer, 200 μmol/L of each dNTP, and 2 U of *Taq* DNA polymerase (Promega, Madison, WI), diluted in a buffer recommended by the manufacturer in a total volume of 50 μL in a Perkin Elmer Cetus cycler (Norwalk, CT). The first PCR cycle consisted of 10 minutes denaturation at 95°C, 1½ minute primer annealing at 56°C, and 1½ minute extension at 72°C. This was followed by 35 cycles in which the denaturing time was decreased to 1 minute. The last cycle was followed by 8 minutes at 72°C to complete extension. The sense primer in the second PCR contained a mismatch that created an *Nla*III restriction site only in *FcγRIIIA-158V*-encoding DNA (A014: 5'-atc aga ttc gAT CCT ACT TCT GCA GGG GGC AT-3'; uppercase characters denote annealing nucleotides, lowercase characters denote nonannealing nucleotides), the antisense primer was chosen just 5' of the fourth intron (A016: 5'-acg tgc tga gCT TGA GTG ATG GTG ATG TTC AC-3'). This "nested" PCR was performed with 1 μL of the amplified fragment, 150 ng of each primer, 200 μmol/L of each dNTP, and 2 U of *Taq* DNA polymerase, diluted in the recommended buffer. The first cycle consisted of 5 minutes' denaturing at 95°C, 1 minute primer annealing at 64°C, and 1 minute extension at 72°C. This was followed by 35 cycles in which the denaturing time was 1 minute. The last cycle was followed by 9½ minutes at 72°C to complete extension. The 94-bp fragment was digested with *Nla*III, and digested fragments were electrophoresed in 10% polyacrylamide gels, stained with ethidium bromide, and visualized with UV light. Cycle sequencing of first-round fragments to check for specificity was performed with <sup>32</sup>P end-labeled primer A016 with the Life Technologies cycle sequencing kit. Genomic DNA of individuals whose *FcγRIIIA* encoding cDNA sequence was known were used to optimize the PCR assay.

***IgG-binding experiments.*** Quantification of IgG binding to natural killer (NK) cells of genotyped donors was performed as previously described.<sup>17</sup> In short, mononuclear cells were pretreated with 0.1% (wt/vol) lactic acid (pH 3.9) to remove NK-cell-associated IgG. This treatment did not alter *FcγRIIIA* expression as measured with CD16 MoAb CLBFCrgran1 (not shown). The cells were incubated with saturating amounts of human IgG subclasses purified from sera of patients suffering from multiple myeloma. The antibodies were at least partially aggregated, because binding to PMN was observed with the IgG1 and IgG3 preparations (not shown). After washing, bound IgG was detected by FITC-labeled F(ab')<sub>2</sub> fragments of goat-antihuman-IgG (Kallestad, South Austin, TX), and NK cells were identified with PE-labeled CD56. Only CD56<sup>+</sup> lymphocytes were analyzed in a FACScan flowcytometer.

***Statistical analysis.*** The data were analyzed with the Student's *t*-test and the  $\chi^2$ -test. Data with different standard deviations (SDs) were compared with the Welch's approximate *t*-test. *P* values below .05 were considered significant.

## RESULTS

***FcγRIIIA-158V/F genotyping.*** An *FcγRIIIA*-derived fragment containing the polymorphic site was amplified from genomic DNA with two *FcγRIIIA* gene-specific primers. Subsequently, a nested PCR was performed in which an

*Nla*III restriction site was created only in the *FcγRIIIA-158V* allele. Figure 1 shows digestion of the 94-bp PCR fragment with *Nla*III. In lanes 1 to 3, PCR fragments from homozygous *FcγRIIIA-158FF* donors are not digested by *Nla*III. In lanes 4 to 6, three bands of 94 bp, 61 bp, and 33 bp are visible, indicating the *FcγRIIIA-158VF* heterozygosity of these individuals. Although the fragments in lanes 7 to 9 were from homozygous *FcγRIIIA-158VV* donors, a 94-bp band of low intensity remained, which was not removed by longer digestion, higher enzyme concentrations, or use of isoschizomer *Nsp* I. The 94-bp band in these donors was not a result of amplification of *FcγRIIIB* fragments due to unspecificity of the first-round PCR, because the *FcγRIIIB* gene carries a G at nucleotide position 559, which results in digestion by *Nla*III. Direct sequencing of several first-round PCR products confirmed the *FcγRIIIA* gene specificity of the assay and the *FcγRIIIA-158* genotype of the donors. Genotyping of 87 healthy white individuals yielded gene frequencies of 0.57 and 0.43 for *FcγRIIIA-158F* and *-158V*, respectively.


Table 1 displays the correlation between the *FcγRIIIA-48* and the *FcγRIIIA-158* phenotypes. A clear linkage was observed between the *FcγRIIIA-158V/F* and the *FcγRIIIA-48L/R/H* polymorphisms ( $\chi^2$ -test, *P* < .001). All *FcγRIIIA-158FF* individuals were homozygous *FcγRIIIA-48LL*, whereas all donors with heterozygous *FcγRIIIA-48LR* or *-48LH* genotypes carried at least one *FcγRIIIA-158V* allele.

***Binding of CD16 MoAbs to NK cells of genotyped donors.*** To determine the influence of the *FcγRIIIA-158V/F* and *-48L/R/H* polymorphisms on the binding of a panel of CD16 MoAbs, we investigated binding patterns by NK cells of genotyped donors (Table 2). The binding of MoAb CLBFCrgran1 was not significantly different among NK cells from all donors. In contrast, *FcγRIIIA-158VF*-positive NK cells from donors homozygous positive for *FcγRIIIA-48L* bound more MEM154 than did NK cells of *FcγRIIIA-158FF*-positive donors (Welch's approximate *t*-test, *P* = .01). In turn, *FcγRIIIA-158VF* NK cells from donors who had only one *FcγRIIIA-48L* allele bound less MEM154 than did *FcγRIIIA-158VV* NK cells (*P* = .04).

Comparison of NK cells of *FcγRIIIA-158VF* phenotyped donors who were either homozygous *FcγRIIIA-48LL*, or heterozygous *-48LR* or *-48LH* showed different binding patterns with MoAb B73.1. NK cells positive for the *FcγRIIIA-48R* or *-48H* isoforms showed reduced binding of B73.1 compared with *FcγRIIIA-48LL* homozygous NK cells (*P* = .05). Binding of MoAb MEM154 was equal among these donors. Three *FcγRIIIA-158VV* individuals who were either homozygous *FcγRIIIA-48RR* or *-48HH* were tested. Binding of MEM154 to cells of these donors was equal compared to the binding to NK cells from *FcγRIIIA-158VV* individuals with a heterozygous *FcγRIIIA-48* phenotype, whereas the binding of B73.1 was diminished (Table 2).

***Binding of IgG subclasses by FcγRIIIA<sup>NK</sup>-158 isoforms in the context of FcγRIIIA<sup>NK</sup>-48 phenotype.*** To determine the functional consequences of the *FcγRIIIA-158V/F* polymorphism, we compared the IgG binding capacity of NK cells from genotyped donors. We studied the differences in IgG binding between individuals who had different

**Fig 1.** *Nla*III restriction analysis of the 94-bp *FcγRIIIA*-specific fragment, containing the polymorphic nucleotide 559. A 1.2-kb *FcγRIIIA*-specific fragment was amplified from genomic DNA, followed by a nested PCR. The sense primer of this nested PCR contained a mismatch that introduced a *Nla*III restriction site only in the *FcγRIIIA-158V* (559G) allele. Homozygous *FcγRIIIA-158FF* fragments were not digested (lanes 1 through 3). Three bands (94 bp, 61 bp, and 33 bp) were visible in heterozygous individuals, whereas homozygous *FcγRIIIA-158VV* fragments were maximally digested (lanes 7 through 9). A 92-bp fragment of low intensity remained in homozygous 559G fragments (lanes 7 through 9).



*FcγRIIIA-158V/F* genotypes, but were identical regarding the *FcγRIIIA-48L/R/H* genotype. Preincubation of PBMC with F(ab') fragments of CD16 MoAb CLBFCrgran1 reduced the binding of IgG to less than 10% of control values, indicating that the interaction was *FcγRIIIA*-mediated (data not shown). As shown in Table 3, lactic acid-treated homozygous *FcγRIIIa-48LL* NK cells from individuals heterozygous at position 158 of *FcγRIIIa* bound more IgG3 than did NK cells from *FcγRIIIa-158FF* phenotyped donors ( $P = .02$ ). Although a trend was observed, the difference in binding of IgG1 was not statistically significant. In one single experiment, NK cells from the one available donor who was homozygous *FcγRIIIa-48LL* as well as *-158VV* bound more IgG3 than did *FcγRIIIa-8LL*-matched homozygous *FcγRIIIa-158FF* or heterozygous donors, without clear differences in binding of IgG1 (data not shown). In individuals who were heterozygous for the *FcγRIIIa-48L/R/H* polymorphism, *FcγRIIIa-158VV*-positive NK cells bound more IgG1 compared with *FcγRIIIa-158VF*-positive NK cells (Table 3; Welch's approximate  $t$ -test,  $P = .03$ ). For these donors, the differences in binding of IgG3 were not statisti-

cally significant, although a trend was observed. When we determined the levels of NK-cell-associated IgG of freshly isolated NK cells, we observed that *FcγRIIIa-158FF*-positive cells carried less IgG than did *FcγRIIIa-158VV*-positive cells. Comparing NK cells from donors of the same *FcγRIIIa-48L/R/H* phenotype, we observed a trend toward higher levels of cytophilic IgG bound by *FcγRIIIa-158VF* and *-158VV*-positive cells, as compared with *FcγRIIIa-158FF*-positive cells (Table 3). The levels of NK-cell-associated IgG of *FcγRIIIa-48LL* and *-158VF*-positive NK cells did not significantly differ from that of *FcγRIIIa-48LR* or *-48LH* NK cells of the same *-158VF* phenotype.

To exclude any effect of the triallelic *FcγRIIIa-48L/R/H* polymorphism on IgG binding, we compared *FcγRIIIa-48LL*-positive NK cells with *FcγRIIIa-48LR*- or *-48LH*-positive NK cells from donors who were all heterozygous *FcγRIIIa-158VF*. As shown in Table 3, no statistically significant differences were observed in either the amount of NK-cell-associated IgG or in the binding of IgG subclasses to lactic acid-treated NK cells. Therefore, we depicted the results of IgG-binding experiments, comparing *FcγRIIIa-158FF* NK-

**Table 1.** *FcγRIIIA-158V/F* Genotypes in White Individuals (n = 87), Typed for *FcγRIIIA-48L/R/H*

<i>FcγRIIIa-158</i>		<i>FcγRIIIa-48L/R/H</i> Phenotype						
Genotype	Phenotype	Total	48LL	48LR	48LH	48RR	48HH	48RH
559T/T	158FF	28	28	—*	—	—	—	—
559G/T	158VF	44	34	4	6	—	—	—
559G/G	158VV	15	4	6	4	1	—†	—

Gene frequencies are 0.57 and 0.43 for *FcγRIIIa-158F* and *FcγRIIIa-158V*, respectively. A clear linkage was observed between the *FcγRIIIA-158F* and the *FcγRIIIA-48L* alleles, as well as between the *FcγRIIIa-158V* and either the *FcγRIIIa-48R* or *-48H* alleles ( $\chi^2$  test;  $P < .001$  in both cases).

\* A dash (—) denotes that in this study none of the tested donors had this genotype.

† In a previous study we described one healthy individual and two unrelated patients suffering from recurrent bacterial and viral infections who were homozygous *FcγRIIIa-48H/H* (De Vries, unpublished data, 1996 and ref 18). These three donors were found to be homozygous *FcγRIIIa-158VV*.

**Table 2. CD16 MoAb Binding (mean fluorescence intensities  $\pm$  SD) of NK Cells From Individuals Genotyped for *Fc $\gamma$ R11IA* Polymorphisms**

Genotype		MoAb			
<i>Fc<math>\gamma</math>R11IA-48</i>	<i>Fc<math>\gamma</math>R11IA-158</i>	Control mIgG2a	CLBFcRgran1	MEM154	B73.1
48LL	158FF	12 $\pm$ 6	1,539 $\pm$ 257	42 $\pm$ 20	303 $\pm$ 176
48LL	158VF	8 $\pm$ 4	1,713 $\pm$ 719	460 $\pm$ 218*	248 $\pm$ 105
48LR or 48LH	158VF	6 $\pm$ 2	1,443 $\pm$ 504	323 $\pm$ 182	121 $\pm$ 51†
48LR or 48LH	158VV	10 $\pm$ 5	1,102 $\pm$ 298	718 $\pm$ 341†	151 $\pm$ 117
48HH‡	158VV	7	1,694	892	55
48RR <sup>  </sup>	158VV	15	1,443	642	103

At least three donors of each genotype were tested. Data were analyzed with the Student's *t*-test and the Welch's approximate *t*-test. *P* values below .05 were considered significant.

\* Statistically significant difference from mean fluorescence intensity of NK cells from *Fc $\gamma$ R11IA-158FF* individuals of the same *Fc $\gamma$ R11IA-48* genotype.

† Significantly different from *Fc $\gamma$ R11IA-48LL* NK cells of the same *Fc $\gamma$ R11IA-158* genotype.

‡ Significantly different from *Fc $\gamma$ R11IA-158VF* NK cells of the same *Fc $\gamma$ R11IA-48* genotype.

§ Two individuals were tested; one healthy control and one patient suffering from recurrent viral infections.

<sup>||</sup> One healthy individual was tested.

cells with *Fc $\gamma$ R11IA-158VV* NK cells, disregarding the *Fc $\gamma$ R11IA-48* phenotype (Fig 2). Significant differences in levels of IgG1 (*P* = .007), IgG3 (.005), IgG4 (.02), and cytophilic IgG (.004) were observed.

### DISCUSSION

Recently we identified a triallelic polymorphism in the membrane-distal Ig-like domain of *Fc $\gamma$ R11IA*, in which a leucine, an arginine, or a histidine can be present at amino acid position 48.<sup>17</sup> In the present report, we functionally characterized a previously described genetic polymorphism of *Fc $\gamma$ R11IA*, encoding either a phenylalanine (F) or a valine (V) at amino acid position 158 in the membrane-proximal Ig-like loop of *Fc $\gamma$ R11IA*.<sup>13</sup> We determined that the gene frequencies for *Fc $\gamma$ R11IA-158F* and *Fc $\gamma$ R11IA-158V* were 0.57 and 0.43, respectively. The *Fc $\gamma$ R11IA-158F* genotype was shown to be clearly linked to the *Fc $\gamma$ R11IA-48L* genotype, whereas the *Fc $\gamma$ R11IA-158V* was found to be linked to *Fc $\gamma$ R11IA-48R* and *-48H*. A linkage between allotypes of the *Fc $\gamma$ R11IA-158V/F* and the *Fc $\gamma$ R11IA-48L/R/H* polymorphisms was expected because the two polymorphisms are located within the same gene.

In our previous work, we attributed differences in binding of several CD16 MoAbs to the amino acid present on position 48 of *Fc $\gamma$ R11IA*. We now show that the binding of

MEM154 depends on the presence of a valine at amino acid position 158 of *Fc $\gamma$ R11IA* and is not influenced by the amino acid polymorphism at position 48. These findings are in conformity with data from Tamm and Schmidt,<sup>19</sup> who found that the epitope recognized by MEM154 is located in the membrane-proximal domain. We did not observe any effect of the *Fc $\gamma$ R11IA-158V/F* polymorphism on B73.1 binding but confirmed our initial observations that only the amino acid at position 48 influenced the binding of MoAb B73.1.<sup>17,18</sup>

The membrane-proximal domain, carrying the *Fc $\gamma$ R11IA-158V/F* polymorphism, is generally accepted to contain the IgG-binding site in *Fc $\gamma$ Rs*, and experiments with mutants of *Fc $\gamma$ R11IB* showed that the membrane-proximal loop is essential for IgG binding in *Fc $\gamma$ R11IB*.<sup>14,15</sup> To study the functional consequences of the *Fc $\gamma$ R11IA-158V/F* polymorphism in the context of the *Fc $\gamma$ R11IA-48L/R/H* polymorphism, we performed IgG binding experiments with NK cells from genotyped donors. NK cells from homozygous *Fc $\gamma$ R11IA-158VV*-positive individuals bound more IgG1 and IgG3 than did *Fc $\gamma$ R11IA-158FF*-positive NK cells, irrespective of the amino acid present on position 48 of the receptor. NK cells of *Fc $\gamma$ R11IA-158VF* heterozygous donors showed intermediate levels of IgG binding, indicating a gene-dosis effect. These data indicate that the donor-dependent differences in IgG binding of *Fc $\gamma$ R11IA* isoforms are attributable to the


**Table 3. Binding of Human IgG Subclasses of NK Cells From Individuals Genotyped for *Fc $\gamma$ R11IA* Polymorphisms (MFI  $\pm$  SD)**

Genotype		Subclass				
<i>Fc<math>\gamma</math>R11IA-48</i>	<i>Fc<math>\gamma</math>R11IA-158</i>	IgG1	IgG2	IgG3	IgG4	Cytophilic IgG
48LL	158FF	913 $\pm$ 317	58 $\pm$ 33	390 $\pm$ 131	106 $\pm$ 104	337 $\pm$ 159
48LL	158VF	1,257 $\pm$ 608	124 $\pm$ 126	912 $\pm$ 286*	413 $\pm$ 178	695 $\pm$ 405
48LR or 48LH	158VF	1,243 $\pm$ 194	155 $\pm$ 133	746 $\pm$ 230	548 $\pm$ 202	1,139 $\pm$ 542
48LR or 48LH	158VV	1,814 $\pm$ 507†	173 $\pm$ 98	1,053 $\pm$ 487	487 $\pm$ 286	1,788 $\pm$ 796

At least three donors of each genotype were tested. Data were analyzed with the Student's *t*-test and the Welch's approximate *t*-test. *P* values below .05 were considered significant.

\* Statistically significant difference from IgG3 binding by NK cells from *Fc $\gamma$ R11IA-158V/F* individuals of the same *Fc $\gamma$ R11IA-48* genotype.

† Significantly different from *Fc $\gamma$ R11IA-158V/F* cells of the same *Fc $\gamma$ R11IA-48* genotype.



**Fig 2.** Fc $\gamma$ RIIIa<sup>NK</sup>-158V binds more IgG than does Fc $\gamma$ RIIIa<sup>NK</sup>-158F. IgG binding by NK cells from individuals either homozygous Fc $\gamma$ RIIIA-158FF (■) or homozygous Fc $\gamma$ RIIIA-158VV (□) was compared, irrespective of the Fc $\gamma$ RIIIa-48L/R/H genotype. At least three different donors of each genotype were tested. The level of cytophilic IgG and the binding of IgG1, IgG3, and IgG4 was significantly higher in NK cell from Fc $\gamma$ RIIIA-158VV individuals ( $P < .05$  in all cases).

Fc $\gamma$ RIIIa-158 polymorphism and not to the Fc $\gamma$ RIIIa-48L/R/H polymorphism, as we previously suggested.<sup>17</sup> Due to the linkage between the two Fc $\gamma$ RIIIA polymorphisms, the Fc $\gamma$ RIIIa-48LL-positive donors described in our previous work were all homozygous Fc $\gamma$ RIIIa-158FF and therefore their NK cells showed low IgG binding. In contrast, the tested Fc $\gamma$ RIIIa-48LR or -48LH-positive donors all carried one or two Fc $\gamma$ RIIIa-158V alleles and therefore bound high levels of IgG.

Vance et al<sup>20</sup> described a donor-dependent difference in binding of CD16 MoAb 3G8 and monomeric IgG to NK cells. Although we did not observe clear differences in 3G8 binding among our donors (not shown), our IgG binding experiments suggest that the polymorphism described by these investigators might be the result of different Fc $\gamma$ RIIIa-158V/F phenotypes.

Hulett and Hogarth<sup>21</sup> extrapolated Fc $\gamma$ RII data to Fc $\gamma$ RIII and suggested that the phenylalanine on position 158 of Fc $\gamma$ RIIIa might be partly responsible for the medium affinity of the receptor for IgG, thus attributing the low-affinity receptor of Fc $\gamma$ RIIIb to the valine at position 158. Our results are contradicting with this theory because Fc $\gamma$ RIIIa-158V bound more IgG than did Fc $\gamma$ RIIIa-158F. Recent studies suggest that association of Fc $\gamma$ RIIIa with the Fc $\epsilon$ RI- $\gamma$  chain might be responsible for the medium affinity, because association of Fc $\gamma$ RI with the  $\gamma$ -chain increases the affinity of the receptor for IgG, and results from experiments with Fc $\gamma$ RI-Ib mutants that could associate with the  $\gamma$ -chain pointed in the same direction.<sup>22</sup>

The clinical consequences of our findings remain to be established. A higher affinity for IgG could result in higher clearance of immune complexes in patients suffering from (auto)immune disease. On the other hand, a higher amount of cytophilic IgG might imply a decreased availability of Fc $\gamma$ RIIIa and, thus, obstruction of receptor-immune complex interaction. Recently we<sup>23</sup> and others<sup>18</sup> separately described children with a homozygous Fc $\gamma$ RIIIA-48HH genotype suffering from recurrent viral infections. We genotyped the two

unrelated patients from the former study and found that they were both homozygous Fc $\gamma$ RIIIA-158VV. Previous work has suggested that cytophilic IgG on NK cells has inhibitory effects on natural cytotoxicity.<sup>24,25</sup> It is tempting to speculate that in the described pediatric patients, NK cells are loaded with a high amount of Fc $\gamma$ RIIIa-158V-bound IgG, thereby hampering a proper antiviral response.

#### ACKNOWLEDGMENT

We thank Dr E. De Vries (Department of Pediatrics of the University Hospital Leiden, Leiden, The Netherlands) for providing the patient samples.

#### REFERENCES

- De Haas M, Vosseveld PJM, Von dem Borne AEGKr, Roos D: Fc $\gamma$  receptors of phagocytes. *J Lab Clin Med* 126:330, 1995
- Bredius RGM, Fijen CAP, De Haas M, Kuijper EJ, Weening RS, Van de Winkel JGJ, Out TA: Role of neutrophil Fc $\gamma$ R II (CD32) and Fc $\gamma$ R IIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. *Immunology* 83:624, 1994
- Salmon JE, Edberg JC, Kimberly RP: Fc $\gamma$  receptor III on human neutrophils. Allelic variants have functionally distinct capacities. *J Clin Invest* 85:1287, 1990
- Salmon JE, Edberg JC, Brogle NL, Kimberly RP: Allelic polymorphisms of human Fc $\gamma$  receptor IIA and Fc $\gamma$  receptor IIIB. Independent mechanisms for differences in human phagocyte function. *J Clin Invest* 89:1274, 1992
- Salmon JE, Millard SS, Brogle NL, Kimberly RP: Fc $\gamma$  receptor IIb enhances Fc $\gamma$  receptor IIA function in an oxidant dependent and allele-sensitive manner. *J Clin Invest* 95:2877, 1995
- Parren PWI, Warmerdam PAM, Boeije LCM, Arts J, Westervaal NAC, Vlug A, Capel PJA, Aarden LA, Van de Winkel JGJ: On the interaction of IgG subclasses with the low-affinity Fc $\gamma$ RIIIa (CD32) on human monocytes, neutrophils and platelets. *J Clin Invest* 90:1537, 1992
- Sanders LAM, Van de Winkel JGJ, Rijkers GT, Voorhorst-Ogink MM, De Haas M, Capel PJA, Zegers BJM: Fc $\gamma$  receptor IIA (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. *J Infect Dis* 170:854, 1994
- Bredius RGM, Derkx BHF, Fijen CAP, De Wit TPM, De Haas M, Weening RS, Van de Winkel JGJ, Out TA: Fc $\gamma$  Receptor IIA (CD32) polymorphism in fulminant meningococcal septic shock in children. *J Infect Dis* 170:848, 1994
- Burgess JK, Lindeman R, Chesterman CN, Chong BH: Single amino acid mutation of Fc receptor is associated with the development of heparin-induced thrombocytopenia. *Br J Haematol* 91:761, 1995
- Wilson ME, Kalmar JR: Fc $\gamma$ RIIIa (CD32): A potential marker defining susceptibility to localized juvenile periodontitis. *J Periodontol* 67:323, 1996
- Duits AJ, Bootsma H, Derksen RHWM, Spronk PE, Kater L, Kallenberg CGM, Capel PJA, Westerdaal NAC, Spierenburg GT, Gmelig-Meyling FHJ, Van de Winkel JGJ: Skewed distribution of IgG Fc receptor IIA (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. *Arthritis Rheum* 39:1832, 1995
- Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MGE, Kimberly RP: Fc $\gamma$ RIIIA alleles are heritable risk factors for Lupus nephritis in African-Americans. *J Clin Invest* 97:1348, 1996
- Ravetch JV, Perussia B: Alternative membrane forms of Fc $\gamma$ RIII (CD16) on human NK cells and neutrophils: Cell-type spe-

cific expression of two genes which differ in single nucleotide substitutions. *J Exp Med* 170:481, 1989

14. Hibbs ML, Tolvanen M, Carpen O: Membrane-proximal Ig-like domain of Fc $\gamma$ RIII (CD16) contains residues critical for ligand binding. *J Immunol* 152:4466, 1994

15. Tamm A, Kister A, Nolte KU, Gessner JE, Schmidt RE: The IgG binding site of human Fc $\gamma$ RIIIB receptor involves CC' and FG loops of the membrane-proximal domain. *J Biol Chem* 271:3659, 1996

16. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G: Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. *J Immunol* 130:2133, 1983

17. De Haas M, Koene HR, Kleijer M, De Vries E, Simsek S, Van Tol MJD, Roos D, Von dem Borne AEGKr: A triallelic Fc $\gamma$  receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcRIIIa. *J Immunol* 156:2948, 1996

18. De Vries E, Koene HR, Vossen JM, Gratama JW, Von dem Borne AEGKr, Waaijer JLM, Haraldsson A, De Haas M, Van Tol MJD: Identification of an unusual Fc $\gamma$  receptor IIIa on natural killer cells in a patient with recurrent infections. *Blood* 88:3022, 1996

19. Tamm A, Schmidt RE: The binding epitopes of human CD16

(Fc $\gamma$ RIII) monoclonal antibodies. Implications for ligand binding. *J Immunol* 157:1576, 1996

20. Vance BA, Huizinga TWJ, Wardwell K, Guyre PM: Binding of monomeric human IgG defines an expression polymorphism of Fc $\gamma$ RIII on large granular lymphocyte/natural killer cells. *J Immunol* 151:6429, 1993

21. Hulett MD, Hogarth PM: Molecular basis of Fc receptor function. *Adv Immunol* 57:1, 1994

22. Miller KL, Duchemin A, Anderson CL: A novel role for the Fc receptor gamma subunit: Enhancement of Fc $\gamma$ R ligand affinity. *J Exp Med* 183:2227, 1996

23. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T: Natural killer (NK) cell deficiency associated with an epitope-deficient Fc $\gamma$  receptor type IIIA (CD16-II). *Clin Exp Immunol* 103:408, 1996

24. Sulica A, Gherman M, Galatiuc C, Manciulea M, Herberman RB: Inhibition of human natural killer cell activity by cytophilic immunoglobulin G. *J Immunol* 128:1031, 1982

25. Gherman M, Manciulea M, Bancu AC, Sulica A, Stanworth DR, Herberman RB: Regulation of human natural cytotoxicity by IgG. Characterization of the structural site on monomeric IgG responsible for inhibiting natural killer cell activity. *Mol Immunol* 24:743, 1987